The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
A computer model was developed with decision analysis software to explore the long-term clinical and economic outcomes of alcohol abstinence maintenance with either standard counselling therapy or standard therapy plus 48 weeks of adjuvant acamprosate in detoxified alcoholic patients. Important complications of alcoholism were modelled using Markov processes, and included relapse (return to drinking), alcohol-related hepatic disease, acute and chronic pancreatitis, acute and chronic gastritis, oropharyngeal carcinoma, oesophageal carcinoma, alcoholic cardiomyopathy, alcohol-related peripheral neuropathy, alcoholic psychosis, accidental death, and suicide. Probabilities of developing complications were dependent on whether the patients within the cohort remained abstinent or had relapsed. Relapse rates, probabilities, and costs for acamprosate therapy and treatment of complications were taken from published literature. The analysis was performed from the German health insurance perspective. Life expectancy and total lifetime costs (costs of initial abstinence maintenance therapy plus costs of complications) were calculated for a typical male cohort with average age of 41 years, 80% with fatty liver, 15% with cirrhosis, 22% with chronic pancreatitis, and 1% with alcoholic cardiomyopathy at baseline. Life expectancy with and without acamprosate therapy was 15.90 and 14.70 years respectively, and discounted (5% per annum) average total lifetime costs per patient were DEM 46 448 and DEM 49 549 respectively. We conclude that, despite the acquisition costs of DEM 2177, adjuvant acamprosate therapy was both clinically and economically attractive under conservative assumptions.
Palmer
A J
AJ
IMIB, Institute for Medical Informatics and Biostatistics, Riehen, Switzerland, Merk-Lipha S.A., Lyon, France.
Neeser
K
K
Weiss
C
C
Brandt
A
A
Comte
S
S
Fox
M
M
D000077443:Acamprosate; D000328:Adult; D000427:Alcohol Deterrents / Q000191:economics* / Q000627:therapeutic use; D000437:Alcoholism / Q000191:economics* / Q000628:therapy; D015331:Cohort Studies; D003362:Cost-Benefit Analysis / Q000191:economics; D006801:Humans; D008017:Life Expectancy; D008108:Liver Diseases, Alcoholic / Q000191:economics / Q000628:therapy; D008297:Male; D018803:Models, Economic; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013654:Taurine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D013695:Temperance / Q000191:economics*
D000427:Alcohol Deterrents; D013654:Taurine; D000077443:Acamprosate